Omnicell, Inc. (OMCL) reported third-quarter 2024 adjusted earnings per share (EPS) of 56 cents, which declined 9.7% year over year. However, the metric beat the Zacks Consensus Estimate by 36.6%.Adjustments include one-time expenses like share-based compensations, the amortization of acquired intangibles, acquisition-related expenses and RDS restructuring.GAAP EPS was 19 cents, up 58.3% from the 2023 figure.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Following the announcement, O ...

Shares of Omnicell (OMCL) have been strong performers lately, with the stock up 25.4% over the past month. The stock hit a new 52-week high of $55.75 in the previous session. Omnicell has gained 41% since the start of the year compared to the 4.2% move for the Zacks Medical sector and the -47.6% return for the Zacks Medical Info Systems industry.What's Driving the Outperformance?The stock has an impressive record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of ...

Financial Data and Key Metrics Changes - Total revenue for Q3 2024 was $282 million, a sequential increase of $6 million from the previous quarter but a decrease of $16 million compared to Q3 2023 [18][34] - GAAP earnings per share for Q3 2024 were $0.19, up from $0.08 in the prior quarter and $0.12 in Q3 2023 [18][38] - Non-GAAP earnings per share for Q3 2024 were $0.56, compared to $0.51 in the prior quarter and $0.62 in the same period last year [19][39] - Non-GAAP EBITDA for Q3 2024 was $39 million, a decrease of $1 million from the previous quarter and a decrease of $2 million from the same period last year [19][39] - Cash and cash equivalents at the end of Q3 2024 were $571 million, up from $557 million as of June 30, 2024 [40] Business Line Data and Key Metrics Changes - Product revenues for Q3 2024 were $158 million, an increase of $2 million over the previous quarter but down $30 million compared to Q3 2023 [35] - Service revenues for Q3 2024 were $124 million, an increase of $4 million over the previous quarter and an increase of $14 million compared to Q3 2023 [35] - Advanced Services, including EnlivenHealth and Specialty Pharmacy Services, contributed positively to revenue growth [34] Market Data and Key Metrics Changes - The macroeconomic landscape is showing signs of stabilization, which is favorable for increased demand for capital projects and system modernization [14] - The company is seeing strong demand for its XT Amplify program, which is resonating well with customers [15][20] Company Strategy and Development Direction - The company is focused on transforming the Pharmacy Care delivery model to improve customer experiences and patient outcomes [10] - A new Chief Operating Officer has been appointed to lead operational change management initiatives [11][12] - The company is investing in next-generation upgrades and outcomes-based solutions for its XT fleet of automated medication dispensing systems [15] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the stabilizing macroeconomic environment and its impact on customer spending [14][78] - There is a focus on long-term strategic investments rather than opportunistic spending, indicating a shift in customer priorities [78] - The company has raised its full-year 2024 guidance for bookings and total revenues, reflecting strong commercial momentum [42][43] Other Important Information - The company plans to change its bookings metric starting in 2025 to better reflect its focus on growing recurring revenue [46][48] - The company is exploring operational efficiencies and cost optimization initiatives as part of its ongoing strategy [71][72] Q&A Session Summary Question: Impact of hurricanes on revenue - Management confirmed that hurricanes did not impact Q3 revenue and expects Q4 revenue to increase [50] Question: Future product gross margins - Management expects gross margins to improve over time as advanced services scale and customer feedback from XT Amplify is positive [51][52] Question: XT Amplify upgrade cycle - Management indicated that XT Amplify is more than just an upgrade cycle and is expected to drive new technology adoption [54][55] Question: Cabinet contribution and lifecycle - Management noted that while the XT upgrade cycle is cycling down, there are opportunities for expansion with the existing XT fleet [56][57] Question: Specialty pharmacy business impact from Inflation Reduction Act - Management believes the market for specialty pharmacy has broadened, allowing smaller hospital systems to adopt these services [66] Question: Cost optimization initiatives - Management is focused on operational efficiencies and will continue to explore opportunities for improvement [70][72] Question: Market stabilization and spending priorities - Management noted that strategic investments are being prioritized, with customers engaging in multiyear discussions [78] Question: Bookings guidance and momentum - Management expressed confidence in achieving bookings guidance due to improved economic conditions and new product launches [104][106]

Omnicell (OMCL) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.62 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 36.59%. A quarter ago, it was expected that this Omnicell Inc. Would post earnings of $0.16 per share when it actually produced earnings of $0.51, delivering a surprise of 218.75%. Over the last four quarters, the company ...

Exhibit 99.1 Contact: Kathleen Nemeth Omnicell, Inc. Senior Vice President, Investor Relations 4220 North Freeway 650-435-3318 Fort Worth, TX 76137 Kathleen.Nemeth@Omnicell.com Omnicell Announces Third Quarter 2024 Results Omnicell delivers solid third quarter financial results Total revenues of $282 million GAAP net income per diluted share of $0.19 Non-GAAP net income per diluted share of $0.56 Raises 2024 non-GAAP EBITDA and non-GAAP earnings per share guidance FORT WORTH, Texas -- October 30, 2024 -- Om ...

For Immediate ReleaseChicago, IL – October 29, 2024 – Today, Zacks Equity Research like Inspire Medical Systems (INSP) , 10x Genomics (TXG) and Omnicell, Inc. (OMCL) .Industry: Medical Info SystemsLink: https://www.zacks.com/commentary/2358816/3-medical-info-systems-stocks-to-gain-from-healthcare-digitizationStarting from healthcare resource management to efficient handling of medical records and patient data, the Medical Info Systems industry is rapidly expanding its boundaries with each passing day. Banki ...

Omnicell (OMCL) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. Indiv ...

Group 1: Omnicell, Inc. (OMCL) - Omnicell, Inc. is a pharmaceutical technology company with a Zacks Rank of 1 [1] - The Zacks Consensus Estimate for Omnicell's current year earnings has increased by 16.7% over the last 60 days [1] - Omnicell's shares have gained 56.3% over the last three months, significantly outperforming the S&P 500, which advanced by 2.3% [1] - The company has a Momentum Score of B [1] Group 2: ServisFirst Bancshares, Inc. (SFBS) - ServisFirst Bancshares, Inc. is a bank holding company with a Zacks Rank of 1 [2] - The Zacks Consensus Estimate for ServisFirst Bancshares' current year earnings has increased by 1.8% over the last 60 days [2] - ServisFirst Bancshares' shares have gained 28.5% over the last three months, also outperforming the S&P 500's advance of 2.3% [2] - The company possesses a Momentum Score of A [2]

Omnicell (OMCL) is moving closer to achieving the industry-defined vision of Autonomous Pharmacy through automation and advanced services across its cloud-based platform. The company is on track to meet its 2025 financial goals, supported by increasing tech services and long-term customer partnerships. Its strategic expansion into new regions is also encouraging. However, headwinds from competitive pressures and macroeconomic challenges could adversely affect the company's performance. In the past year, thi ...

Investors might want to bet on Omnicell (OMCL) , as earnings estimates for this company have been showing solid improvement lately. The stock has already gained solid short-term price momentum, and this trend might continue with its still improving earnings outlook. The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this Omnicell Inc. Should get reflected in its stock price. After all, empirical research shows a strong correlation between trend ...